Clinical Oncology: Case Reports.

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Orally Administered Multiple Dose Saltikva (Salmonella-IL2) in Conjunction with Folfirinox in a Patient with Stage IV Pancreatic Cancer: A Case Report

Compassionate use of Saltikva was sought for a patient with stage 4, metastatic pancreatic cancer. Approval was granted for an n=1 multiple dose (every 2 week) trial with concomitant FOLFIRINOX. Now, at 15 months, this patient has not experienced any toxicity to Saltikva, continues therapy, has normalized CA19-9 levels, maintained her immunologic cell populations despite cytotoxic chemotherapy, demonstrated a strong NK cell response, and has a radiologic regression of metastatic tumor burden with a complete absence of tumor activity by PET scan. 

Special Features

Full Text

View

Track Your Manuscript

Recommended Conferences

Share This Page

Media Partners

Associations